Boothbay Fund Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Boothbay Fund Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-44,700	Closed	-$7.6M	–	2277
2025 Q4	$7.6M	Buy	44,700 +19,100	+75%	+$2.93M	0.11%	190
2025 Q3	$3.37M	Buy	+25,600	New	+$3.07M	0.05%	428
2024 Q1	–	Sell	-8,400	Closed	-$1.03M	–	1755
2023 Q4	$1.03M	Hold	8,400	–	–	0.03%	725
2023 Q3	$1.09M	Buy	+8,400	New	+$1.12M	0.03%	730
2021 Q2	–	Sell	-116	Closed	-$1.91M	–	1980
2021 Q1	$1.91M	Buy	+116	New	+$19.1K	0.07%	343

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boothbay Fund Management's JAZZ Position: Q1 2026 in Review

Boothbay Fund Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 92% in Q1 2026, selling an estimated $7.31M and leaving 3,725 shares worth $704K. The position accounts for 0.01% of the portfolio, ranked #1150.

Boothbay Fund Management first reported a position in JAZZ in Q1 2018 and has held it in 9 quarters since. The position peaked at $7.75M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Boothbay Fund Management held 3,725 shares of Jazz Pharmaceuticals worth $704K as of Q1 2026.
Boothbay Fund Management sold 41,842 Jazz Pharmaceuticals shares in Q1 2026, an estimated $7.31M.
Jazz Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1150 holding.
Boothbay Fund Management first reported a position in Jazz Pharmaceuticals in Q1 2018 and has held it in 9 quarters since.
Boothbay Fund Management's Jazz Pharmaceuticals position peaked at $7.75M in Q4 2025.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.